Chengdu Olymvax Biopharmaceuticals Inc.

SHSE:688319 株式レポート

時価総額:CN¥3.6b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Chengdu Olymvax Biopharmaceuticals マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Shaowen Fan

最高経営責任者

CN¥650.5k

報酬総額

CEO給与比率n/a
CEO在任期間14.4yrs
CEOの所有権3.9%
経営陣の平均在職期間データなし
取締役会の平均在任期間9.5yrs

経営陣の近況

Recent updates

What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Jun 24
What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

May 28
Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Apr 18
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Mar 26
These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

CEO(最高経営責任者

Shaowen Fan (71 yo)

14.4yrs

在職期間

CN¥650,500

報酬

Mr. Shaowen Fan is Genenral Manager & Chairman of the Board of Chengdu Olymvax Biopharmaceuticals Inc. since 2019.


取締役

名称ポジション在職期間報酬所有権
Shaowen Fan
Chairman of the Board & GM14.4yrsCN¥650.50k3.87%
CN¥ 140.6m
Yunhui Yu
Director11yrsCN¥30.00k0.020%
CN¥ 716.1k
Pengfei Zhang
Chairman of Supervisory Board8yrsデータなし6.38%
CN¥ 231.7m
Fan Fan
Executive Deputy GM & Vice Chairman of the Board14.4yrsCN¥607.50k7.53%
CN¥ 273.9m
Cheng Hu
Directorno dataCN¥3.10m1.64%
CN¥ 59.7m
Aimin Chen
Directorno dataCN¥879.30k0.16%
CN¥ 5.7m
Lu Lu
Employee Representative Directorno dataCN¥195.00k0.074%
CN¥ 2.7m
Shao Ping He
Independent Director5.2yrsCN¥60.00kデータなし
Hua Yan
Supervisor2.1yrsデータなし0.20%
CN¥ 7.3m

9.5yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: 688319の 取締役会経験豊富 であると考えられます ( 9.5年の平均在任期間)。